Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Post by SoCalLifeon Oct 02, 2020 12:27pm
149 Views
Post# 31658153

Trading at 1x Net asset value

Trading at 1x Net asset valueAnother Q in the books.  

This company is ridiculously cheap.  Trading at 1x asset value, loads of cash to deploy, solid revenue, and making acquisitions... Finally....
EPS will scare away technical computer analysis at over 100x but I suspect as they reel in the expenses and realize more from recent acquisitions, that will normalize to below 20

No brainer buy here.  


6 analysts covering the stock.  all 6 are buys.  low target is 8 bucks, highs over 10.50

RBC = $8
Raymond James = 10.25
Stifel Nicolaus = 10.50
Conaccord = 8
National Bank = 8.25
bloom burton = 10.64
mackie = 8.9


Good luck all involved!!

Let's see a dividend!

Bullboard Posts